| P&L Statement | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue | 10521 | 10901 | 11011 |
| Cost of Material Consumed | 3837 | 3931 | 3468 |
| Change in Inventory | -74 | -84 | 158 |
| Gross Margins | 63.44 | 63.94 | 68.5 |
| Employee Benefit Expenses | 3346 | 3683 | 3867 |
| Other Expenses | 2438 | 2505 | 2183 |
| EBITDA | 564 | 866 | 1335 |
| OPM | 9.16 | 7.94 | 12.12 |
| Other Income | 102 | 154 | 201 |
| Finance Cost | 11 | 15 | 13 |
| D&A | 65 | 62 | 70 |
| EBIT | 899 | 804 | 1265 |
| EBIT Margins | 8.54 | 7.38 | 11.49 |
| PBT | 990 | 943 | 1453 |
| PBT Margins | 9.41 | 8.65 | 13.2 |
| Tax | 303 | 243 | 391 |
| PAT | 687 | 700 | 1062 |
| NPM | 6.53 | 6.42 | 9.64 |
| EPS | 80.71 | 82.24 | 124.77 |
| Financial Ratios | 2019 | 2020 | 2021 |
|---|---|---|---|
| Operating Profit Margin | 9.16 | 7.94 | 12.12 |
| Net Profit Margin | 6.53 | 6.42 | 9.64 |
| Earning Per Share (Diluted) | 80.71 | 82.24 | 124.77 |
| Assets | 2019 | 2020 | 2021 |
|---|---|---|---|
| Fixed Assets | 511 | 581 | 577 |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Trade Receivables | 1026 | 1162 | 1324 |
| Inventory | 2245 | 2356 | 2139 |
| Other Assets | 3481 | 4048 | 5612 |
| Total Assets | 7263 | 8147 | 9662 |
| Liabilities | 2019 | 2020 | 2021 |
|---|---|---|---|
| Share Capital | 85.12 | 85.12 | 85.12 |
| FV | 10 | 10 | 10 |
| Reserves | 5259 | 5946 | 6987 |
| Borrowings | 209 | 208 | 208 |
| Trade Payables | 628 | 570 | 349 |
| Other Liabilities | 1081.88 | 1337.88 | 1990.88 |
| Total Liabilities | 7263 | 8147 | 9662 |
| Cash-Flow Statement | 2019 | 2020 | 2021 |
|---|---|---|---|
| PBT | 989 | 942 | 1452 |
| OPBWC | 963 | 868 | 1335 |
| Change in Receivables | -194 | -79 | -339 |
| Change in Inventories | -38 | -111 | 206 |
| Change in Payables | 171 | -19 | 25 |
| Other Changes | 0 | - | 0 |
| Working Capital Change | -61 | -209 | -108 |
| Cash Generated From Operations | 902 | 659 | 1227 |
| Tax | -167 | -283 | -222 |
| Cash Flow From Operations | 735 | 376 | 1005 |
| Purchase of PPE | -24 | -135 | -70 |
| Sale of PPE | 0 | 0 | 0 |
| Cash Flow From Investment | 78 | 16 | 130 |
| Borrowing | 672 | 173 | 753 |
| Dividend | 8 | 13 | 8 |
| Equity | 0 | 0 | 0 |
| Others From Financing | -1373 | -390 | -1535 |
| Cash Flow from Financing | -693 | -204 | -774 |
| Net Cash Generated | 120 | 188 | 361 |
| Cash at the Start | 1022 | 1142 | 1331 |
| Cash at the End | 1142 | 1330 | 1692 |
Deys Medical Stores (Mfg) Limited is one of India’s oldest and most respected pharmaceutical companies, known for manufacturing a wide range of essential medicines, healthcare products, and therapeutic formulations. With decades of industry experience, the company has built a strong reputation for quality, reliability, and affordability in the pharmaceutical market. Its product portfolio caters to multiple therapeutic segments, making it a trusted name among healthcare professionals and consumers. As the pharmaceutical sector in India continues to expand, Deys Medical Stores maintains its focus on innovation, improved manufacturing practices, and consistent supply, positioning itself for steady long-term growth.
The company’s unlisted shares have generated interest among investors who seek exposure to the pharmaceutical and healthcare sector without relying solely on listed equities. Deys Medical Stores’ operational history, established brand presence, and commitment to quality make its unlisted equity an attractive proposition for diversified portfolios. Investors often view such companies as stable options, given their recurring demand base and ability to withstand market fluctuations. Additionally, the company’s focus on sustainable manufacturing, regulatory compliance, and evolving product lines adds to its credibility and future potential. With healthcare awareness and medicine consumption rising across India, the company stands to benefit from increasing demand for essential and over-the-counter products.
Looking forward, Deys Medical Stores (Mfg) Limited aims to enhance its manufacturing capabilities, expand distribution networks, and explore new therapeutic categories to strengthen its market footprint. For investors, its unlisted shares offer an opportunity to participate in the growth of a well-established pharmaceutical company before it potentially explores larger expansion or listing strategies. As the healthcare industry continues to evolve with modern technologies and evolving consumer needs, the company’s longstanding foundation and operational discipline make it a promising candidate for long-term value creation. Overall, Deys Medical Stores’ unlisted shares appeal to investors seeking stability, sectoral growth, and a strong legacy-backed business.
1. What is the current price of Deys Medical Stores unlisted shares?
The price of Deys Medical Stores unlisted shares varies based on market demand, liquidity, and recent transactions. Prices are typically quoted by unlisted share brokers and updated periodically.
2. How can I buy Deys Medical Stores unlisted shares in India?
You can buy Deys Medical Stores unlisted shares through registered unlisted share dealers or platforms. The process involves price confirmation, payment, and off-market transfer to your Demat account.
3. Can I sell Deys Medical Stores unlisted shares before IPO?
Yes, Deys Medical Stores unlisted shares can be sold before an IPO through the same unlisted share market, subject to the availability of buyers and transfer regulations.
4. Is investing in Deys Medical Stores unlisted shares risky?
Like all unlisted shares, Deys Medical Stores carries risks such as low liquidity, limited disclosures, and price volatility. Investors should assess financials and long-term business prospects before investing.
5. Is Deys Medical Stores planning an IPO?
As of now, there is no officially announced IPO date for Deys Medical Stores. Any IPO plans will depend on company strategy, market conditions, and regulatory approvals.